Updated: October 22, 2025

Why this guide

• This page summarizes evidence-based, non-prescription and prescription alternatives to oral antihistamines for allergic rhinitis, and when to consider disease‑modifying immunotherapy. Figures and recommendations reflect major society guidance and public‑health data (e.g., AAAAI/ACAAI; CDC on allergy burden and season trends) AAAAI allergy statistics, CDC: Allergens & pollen.

How immunotherapy fits

• If the options below don’t provide adequate control or cause side effects, allergen immunotherapy (in‑clinic shots; FDA‑approved tablets for select allergens; or doctor‑guided sublingual drops) can reduce symptoms by changing your immune response over time. Wyndly offers physician‑supervised SLIT for environmental allergies and, when appropriate, can also use FDA‑approved SLIT tablets for grass, ragweed, or dust mite. See our Immunotherapy explainer for details and safety profiles: https://www.wyndly.com/pages/immunotherapy.

Sources cited on this page

• Allergy burden and who might benefit: AAAAI allergy statistics

• Pollen trends and health impact: CDC on allergens & pollen

Introduction

Pollen‑season quick checklist (beyond antihistamines)

• Start/optimize a daily intranasal corticosteroid (e.g., fluticasone, mometasone, budesonide, triamcinolone). Use correct technique and give it 1–2 weeks to work.

• If control is still inadequate, switch to or add a combination intranasal antihistamine–steroid spray (e.g., azelastine/fluticasone or olopatadine/mometasone) for faster, broader relief.

• Predominant watery rhinorrhea? Consider adding an intranasal anticholinergic (ipratropium) for drip control.

• Layer in saline nasal irrigation to mechanically clear allergens and improve comfort and spray delivery.

• Decongestants: reserve for short‑term use. Oral pseudoephedrine may help briefly; avoid topical decongestant sprays beyond 3 days to prevent rebound congestion. Use caution with cardiac disease, hypertension, pregnancy, or insomnia.

• Exposure control during high pollen days: keep windows closed; run HEPA filtration; shower and change clothes after being outdoors; wear sunglasses/hat or a high‑filtration mask outside; bathe pets more often; start your nasal steroid 1–2 weeks before peak season. Check local counts via our pollen tools and city reports.

• When to escalate: persistent symptoms after 2–4 weeks of the above, medication side effects, or a desire for a long‑term solution. Discuss allergen immunotherapy (shots, FDA‑approved tablets for grass/ragweed/dust mite, or at‑home sublingual immunotherapy). Learn how Wyndly’s doctor‑guided SLIT for pollen works.

Helpful links:

• Pollen immunotherapy overview: https://www.wyndly.com/pages/pollen-allergy-immunotherapy

• Learning Center (guides, how‑tos, state/city pollen): https://www.wyndly.com/pages/learning-center

• Pollen and Allergy Reports by city: https://www.wyndly.com/blogs/reports Many patients outgrow the symptom relief of oral OTC antihistamines or want options with better congestion control and fewer systemic effects. Evidence‑based alternatives include intranasal therapies and allergen immunotherapy that address nasal inflammation and, in some cases, the disease mechanism itself. This page summarizes what major allergy societies and the U.S. FDA endorse today (as of October 20, 2025).

Intranasal corticosteroid sprays (INCS): first‑line for persistent allergic rhinitis

• What they are: topical steroids (e.g., fluticasone, mometasone, budesonide, triamcinolone) that reduce nasal mucosal inflammation across the allergy cascade.

• Why they’re first‑line: the 2020 AAAAI/ACAAI Joint Task Force practice parameter identifies INCS as the preferred monotherapy for persistent allergic rhinitis and superior to oral antihistamines for overall nasal control, including congestion.

• Real‑world use: daily, regular dosing with correct technique (aim laterally, away from the septum) improves efficacy and minimizes epistaxis/irritation.

• What to tell patients: onset may begin within 12–24 hours but often requires several days of consistent use; ocular symptoms may also improve. For products and dosing examples, see AAAAI’s nasal spray drug guide.

Combination antihistamine–steroid nasal sprays: when symptoms persist on INCS alone

• What they are: fixed‑dose combinations that add a topical H1 antihistamine to an INCS, improving speed of relief and overall symptom control vs either agent alone in many patients.

• Evidence base: the AAAAI/ACAAI practice parameter supports the additive benefit of combining an intranasal antihistamine with an INCS for allergic and nonallergic rhinitis.

• FDA‑labeled options in the U.S. (indications excerpted):

• Azelastine 137 mcg + fluticasone propionate 50 mcg per spray (Dymista): relief of seasonal allergic rhinitis in adults and children ≥6 years; 1 spray/nostril BID. Key cautions include epistaxis, local mucosal effects, and CYP3A4 inhibitor interactions.

• Olopatadine 600–665 mcg + mometasone furoate 25 mcg per spray (Ryaltris): treatment of seasonal allergic rhinitis in adults and children ≥12 years; 2 sprays/nostril BID. Similar local steroid cautions apply; advise against driving if somnolence occurs.

• When to consider: inadequate control on correctly used INCS, need for faster onset, or prominent sneezing/itch/rhinorrhea alongside congestion.

Saline nasal irrigation: low‑risk adjunct to reduce intranasal allergen load

• Role: mechanically removes allergens and secretions; can improve nasal symptoms and medication performance with minimal risk when used properly.

• Guidance and how‑to: AAAAI provides a recipe and use instructions (including gentle technique and device hygiene). Use sterile, distilled, or previously boiled/cooled water per device instructions.

• Evidence quality: systematic reviews show low‑to‑moderate quality evidence for symptom reduction vs no saline; benefit is adjunctive to pharmacotherapy.

Allergen immunotherapy: disease‑modifying option when medications aren’t enough

• What it is: targeted desensitization with gradually increased doses of clinically relevant allergens to induce immune tolerance (shots in clinic; FDA‑approved tablets at home for select allergens). Professional societies endorse immunotherapy for patients who desire long‑term control, have medication side effects, or have unavoidable exposures.

• FDA‑approved sublingual tablets (SLIT) in 2025:

• House dust mite (Odactra): indicated for HDM‑induced allergic rhinitis with/without conjunctivitis; age expanded to 5–65 years per FDA approval letter on Feb 27–28, 2025. Boxed warning for anaphylaxis; first dose under supervision and epinephrine prescribed.

• Grass pollens: Grastek (Timothy and related species; 5–65 years) and Oralair (five‑grass mix; 5–65 years). Seasonal start (pre‑ and during season) or multi‑year courses for durable effect. First dose observed; epinephrine prescribed.

• Ragweed pollen (Ragwitek): short ragweed; first dose observed; epinephrine prescribed.

• Practice‑parameter positioning: SCIT (shots) and SLIT tablets both reduce allergic rhinitis symptoms; product selection depends on allergen profile, access, age, preferences, and safety considerations. (Note: custom liquid “drops” remain off‑label in the U.S.)

Where do other options fit?

• Oral and intranasal decongestants: useful short‑term for congestion; avoid intranasal agents beyond a few days to prevent rebound (limited 4‑week add‑on in select regimens per parameter). Use oral pseudoephedrine with caution and avoid in pregnancy’s first trimester.

• Cromolyn (intranasal mast‑cell stabilizer): safe but less potent; requires frequent dosing. See AAAAI drug guide.

• Leukotriene receptor antagonists (e.g., montelukast): reserve for patients who fail/intolerate alternatives due to limited benefit–risk for rhinitis alone and FDA boxed warning on neuropsychiatric effects.

Quick selection guide

Implementation checklist for clinicians

• Confirm allergic phenotype and severity; review technique and adherence before escalating.

• Start INCS for persistent disease; reassess in 2–4 weeks.

• If still symptomatic, consider combination intranasal antihistamine–steroid spray.

• Layer saline irrigation for comfort and delivery optimization.

• For long‑term control or medication intolerance, review SCIT vs FDA‑approved SLIT tablets, supervise first SLIT dose, and prescribe epinephrine as required.

Related resources from Wyndly

• Learn how immunotherapy works, efficacy, safety, and who benefits: see our Immunotherapy explainer.

• For a deeper clinical overview and patient‑friendly handouts, see our Best Allergy Immunotherapy Guide.